Significant muscle loss after stereotactic body radiotherapy predicts worse survival in patients with hepatocellular carcinoma
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The relationship between sarcopenia and treatment outcomes, especially in patients with hepatocellular carcinoma (HCC) undergoing stereotactic body radiotherapy (SBRT) has not been well-explored. This study aimed to investigate the effects of sarcopenia on the survival and toxicity after SBRT in patients with HCC. We included 137 patients with HCC treated with SBRT between 2008 and 2018. Sarcopenia was defined as a skeletal muscle index (SMI) of < 49 cm 2/m 2 for men and < 31 cm 2/m 2 for women using computed tomography images at the mid-level of the third lumbar vertebra. The SMI change was presented as the change per 90 days. The Kaplan–Meier method was used for survival estimation, and the Cox regression was used to determine prognosticators. Sarcopenia was present in 67 of 137 eligible patients. With the median follow-up of 14.1 months and 32.7 months in the entire cohort and in those alive, respectively, patients with pre-SBRT sarcopenia or SMI loss ≥ 7% after SBRT had worse overall survival than their counterparts. Significant survival predictors on multivariate analysis were SMI loss ≥ 7% after SBRT [hazard ratio (HR): 1.96, p = 0.013], presence of extrahepatic metastasis (HR: 3.47, p < 0.001), neutrophil-to-lymphocyte ratio (HR: 1.79, p = 0.027), and multiple tumors (HR: 2.19, p = 0.003). Separate Cox models according to the absence and presence of pre-SBRT sarcopenia showed that SMI loss ≥ 7% remained a significant survival predictor in patients with sarcopenia (HR: 3.06, p = 0.017) compared with those without sarcopenia. SMI loss ≥ 7% is also a predictor of the Child–Pugh score increase by ≥ 2 points after SBRT. SMI loss ≥ 7% after SBRT is a significant prognostic factor for worse survival and is associated with liver toxicity compared with pre-SBRT sarcopenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Visser, M., Pahor, M., Taaffe, D. R., Goodpaster, B. H., Simonsick, E. M., Newman, A. B., Nevitt, M., & Harris, T. B. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.5.m326 · Cited by 1,294
Searching for the exercise factor: is IL-6 a candidate?
Pedersen (2003) · Journal of Muscle Research and Cell Motility · doi:10.1023/a:1026070911202 · Cited by 564
Montano-Loza, A. J., Angulo, P., Meza-Junco, J., Prado, C. M. M., Sawyer, M. B., Beaumont, C., Esfandiari, N., Ma, M., & Baracos, V. E. (2016) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12039 · Cited by 512
Research works printed but not linked: 40
- Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424. https://doi.org/10.3322/caac.21492 (2018). · DOI · Paper page
- Bujold, A. et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J. Clin. Oncol. 31(13), 1631–1639. https://doi.org/10.1200/jco.2012.44.1659 (2013). · DOI · Paper page
- Rim, C. H., Kim, H. J. & Seong, J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Radiother. Oncol. 131, 135–144. https://doi.org/10.1016/j.radonc.2018.12.005 (2019). · DOI · Paper page
- Munoz-Schuffenegger, P. et al. Stereotactic body radiation therapy for hepatocellular carcinoma with macrovascular invasion. Radiother. Oncol. 156, 120–126. https://doi.org/10.1016/j.radonc.2020.11.033 (2021). · DOI
- Cruz-Jentoft, A. J. & Sayer, A. A. Sarcopenia. Lancet 393(10191), 2636–2646. https://doi.org/10.1016/s0140-6736(19)31138-9 (2019). · DOI · Paper page
- Williams, G. R., Dunne, R. F., Giri, S., Shachar, S. S. & Caan, B. J. Sarcopenia in the older adult with cancer. J. Clin. Oncol. 39(19), 2068–2078. https://doi.org/10.1200/jco.21.00102 (2021). · DOI · Paper page
- Pamoukdjian, F. et al. Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic review. Clin. Nutr. 37(4), 1101–1113. https://doi.org/10.1016/j.clnu.2017.07.010 (2018). · DOI · Paper page
- Shachar, S. S., Williams, G. R., Muss, H. B. & Nishijima, T. F. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. Eur. J. Cancer. 57, 58–67. https://doi.org/10.1016/j.ejca.2015.12.030 (2016). · DOI · Paper page
- Collins, J., Noble, S., Chester, J., Coles, B. & Byrne, A. The assessment and impact of sarcopenia in lung cancer: A systematic literature review. BMJ Open 4(1), e003697. https://doi.org/10.1136/bmjopen-2013-003697 (2014). · DOI · Paper page
- Lee, J. et al. Skeletal muscle loss is an imaging biomarker of outcome after definitive chemoradiotherapy for locally advanced cervical cancer. Clin. Cancer Res. 24(20), 5028–5036. https://doi.org/10.1158/1078-0432.ccr-18-0788 (2018). · DOI
- Zhang, S. et al. Sarcopenia as a predictor of poor surgical and oncologic outcomes after abdominal surgery for digestive tract cancer: A prospective cohort study. Clin. Nutr. 38(6), 2881–2888. https://doi.org/10.1016/j.clnu.2018.12.025 (2019). · DOI
- van Rijn-Dekker, M. I. et al. Impact of sarcopenia on survival and late toxicity in head and neck cancer patients treated with radiotherapy. Radiother. Oncol. 147, 103–110. https://doi.org/10.1016/j.radonc.2020.03.014 (2020). · DOI
- Abe, S. et al. Preoperative sarcopenia is a poor prognostic factor in lower rectal cancer patients undergoing neoadjuvant chemoradiotherapy: A retrospective study. Int. J. Clin. Oncol. 27(1), 141–153. https://doi.org/10.1007/s10147-021-02062-z (2022). · DOI
- Ebadi, M. et al. Skeletal muscle pathological fat infiltration (myosteatosis) is associated with higher mortality in patients with cirrhosis. Cells https://doi.org/10.3390/cells11081345 (2022). · DOI
- Chang, K. V. et al. Association between loss of skeletal muscle mass and mortality and tumor recurrence in hepatocellular carcinoma: A systematic review and meta-analysis. Liver Cancer. 7(1), 90–103. https://doi.org/10.1159/000484950 (2018). · DOI
- Kim, N. et al. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. Cancer Immunol. Immunother. 70(6), 1593–1603. https://doi.org/10.1007/s00262-020-02794-3 (2021). · DOI
- Iritani, S. et al. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. J. Gastroenterol. 50(3), 323–332. https://doi.org/10.1007/s00535-014-0964-9 (2015). · DOI · Paper page
- Voron, T. et al. Sarcopenia impacts on short- and long-term results of hepatectomy for hepatocellular carcinoma. Ann. Surg. 261(6), 1173–1183. https://doi.org/10.1097/SLA.0000000000000743 (2015). · DOI · Paper page
- Harimoto, N. et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br. J. Surg. 100(11), 1523–1530. https://doi.org/10.1002/bjs.9258 (2013). · DOI · Paper page
- Loosen, S. H. et al. Sarcopenia is a negative prognostic factor in patients undergoing transarterial chemoembolization (TACE) for hepatic malignancies. Cancers https://doi.org/10.3390/cancers11101503 (2019). · DOI
- Nishikawa, H. et al. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy. Oncol. Lett. 14(2), 1637–1647. https://doi.org/10.3892/ol.2017.6287 (2017). · DOI
- Fujita, M. et al. Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: A multicenter study in Tohoku, Japan. Sci. Rep. 12(1), 6479. https://doi.org/10.1038/s41598-022-10514-3 (2022). · doi:10.1038/s41598-022-10514-3
- Huang, W. Y. et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 84(2), 355–361. https://doi.org/10.1016/j.ijrobp.2011.11.058 (2012). · doi:10.1016/j.ijrobp.2011.11.058
- Lencioni, R. & Llovet, J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30(1), 52–60. https://doi.org/10.1055/s-0030-1247132 (2010). · DOI · Paper page
- Shen, W. et al. Total body skeletal muscle and adipose tissue volumes: Estimation from a single abdominal cross-sectional image. J. Appl. Physiol. 97(6), 2333–2338. https://doi.org/10.1152/japplphysiol.00744.2004 (2004). · DOI · Paper page
- Mourtzakis, M. et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl. Physiol. Nutr. Metab. 33(5), 997–1006. https://doi.org/10.1139/h08-075 (2008). · DOI · Paper page
- Yu, J. I. et al. Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial. Radiother. Oncol. 152, 19–25. https://doi.org/10.1016/j.radonc.2020.07.043 (2020). · DOI
- Prado, C. M. et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol. 9(7), 629–635. https://doi.org/10.1016/s1470-2045(08)70153-0 (2008). · DOI · Paper page
- Martin, L. et al. Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31(12), 1539–1547. https://doi.org/10.1200/jco.2012.45.2722 (2013). · DOI · Paper page
- Sakurai, K. et al. Adverse effects of low preoperative skeletal muscle mass in patients undergoing gastrectomy for gastric cancer. Ann. Surg. Oncol. 24(9), 2712–2719. https://doi.org/10.1245/s10434-017-5875-6 (2017). · DOI
- Perisetti, A. et al. Sarcopenia in hepatocellular carcinoma: Current knowledge and future directions. World J. Gastroenterol. 28(4), 432–448. https://doi.org/10.3748/wjg.v28.i4.432 (2022). · DOI
- Xu, L. et al. Preoperative computed tomography-assessed skeletal muscle index is a novel prognostic factor in patients with hepatocellular carcinoma following hepatectomy: A meta-analysis. J. Gastrointest. Oncol. 11(5), 1040–1053. https://doi.org/10.21037/jgo-20-122 (2020). · DOI
- Shiba, S. et al. No deterioration in clinical outcomes of carbon ion radiotherapy for sarcopenia patients with hepatocellular carcinoma. Anticancer Res. 38(6), 3579–3586. https://doi.org/10.21873/anticanres.12631 (2018). · doi:10.21873/anticanres.12631
- Lee, J., Cho, Y., Park, S., Kim, J. W. & Lee, I. J. Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with radiotherapy. Front. Oncol. 9, 1075. https://doi.org/10.3389/fonc.2019.01075 (2019). · DOI
- Templeton, A. J. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. J. Natl. Cancer Inst. 106(6), dju124. https://doi.org/10.1093/jnci/dju124 (2014). · DOI · Paper page
- Haram, A. et al. The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer: A systematic review. J. Surg. Oncol. 115(4), 470–479. https://doi.org/10.1002/jso.24523 (2017). · DOI · Paper page
- Feliciano, E. M. C. et al. Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: Results from the C SCANS study. JAMA Oncol. 3(12), e172319. https://doi.org/10.1001/jamaoncol.2017.2319 (2017). · DOI · Paper page
- Cho, Y. et al. Prognostic significance of sarcopenia with inflammation in patients with head and neck cancer who underwent definitive chemoradiotherapy. Front. Oncol. 8, 457. https://doi.org/10.3389/fonc.2018.00457 (2018). · DOI
- Velec, M. et al. Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 97(5), 939–946. https://doi.org/10.1016/j.ijrobp.2017.01.221 (2017). · DOI
- Chen, L. K. et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J. Am. Med. Dir. Assoc. 21(3), 300–307.e2. https://doi.org/10.1016/j.jamda.2019.12.012 (2020). · DOI · Paper page
Metadata
- Authors
- Yang, J.-F., Huang, W.-Y., Lo, C.-H., Lee, M.-S., Lin, C.-S., Shen, P.-C., Dai, Y.-H., Wang, Y.-F., & Chen, T.-W.
- Venue
- Scientific Reports
- Published
- 2022-11-09
- Volume
- 12
- Issue
- 1
- ISSN
- 2045-2322
- Cited by
- 5
- References
- 4
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Significant muscle loss after stereotactic body radiotherapy predicts worse survival in patients with hepatocellular carcinoma. https://app.cochat.ai/papers/10.1038/s41598-022-21443-6
- The paper
- Yang, J.-F., Huang, W.-Y., Lo, C.-H., Lee, M.-S., Lin, C.-S., Shen, P.-C., Dai, Y.-H., Wang, Y.-F., & Chen, T.-W. (2022). Significant muscle loss after stereotactic body radiotherapy predicts worse survival in patients with hepatocellular carcinoma. Scientific Reports. https://doi.org/10.1038/s41598-022-21443-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.